A monoclonal antibody targeting a protein known as SFPR2 has been shown to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
A monoclonal antibody targeting a protein known as SFPR2 has been shown to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.